[go: up one dir, main page]

NO20044901L - Anvendelse av modifiserte novirhabdoviruser i vaksiner - Google Patents

Anvendelse av modifiserte novirhabdoviruser i vaksiner

Info

Publication number
NO20044901L
NO20044901L NO20044901A NO20044901A NO20044901L NO 20044901 L NO20044901 L NO 20044901L NO 20044901 A NO20044901 A NO 20044901A NO 20044901 A NO20044901 A NO 20044901A NO 20044901 L NO20044901 L NO 20044901L
Authority
NO
Norway
Prior art keywords
novirhabdoviruses
modified
vaccines
inactivated
fish
Prior art date
Application number
NO20044901A
Other languages
English (en)
Other versions
NO328272B1 (no
Inventor
Stephane Biacchesi
Monique Leberre
Maria-Isabel Thoulouze
Michel Bremont
Original Assignee
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agronomique Inst Nat Rech filed Critical Agronomique Inst Nat Rech
Publication of NO20044901L publication Critical patent/NO20044901L/no
Publication of NO328272B1 publication Critical patent/NO328272B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation
    • C12N2760/20162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anvendelse av modifiserte novirhabdovirus der NV-proteingenet er inaktivert for å oppnå vaksiner for anvendelse særlig i fisk.
NO20044901A 2002-05-07 2004-11-10 Modifisert, rekombinant novirhabdovirus, komplementaere DNA-molekyler av genomet av nevnte novirhabdovirus, rekombinant vektor omfattende nevnte DNA-molekyl, vaksine omfattende nevnte novirhabdovirus, DNA-molekyl eller vektor for a oppna et medisinsk produkt. NO328272B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0205702A FR2839453B1 (fr) 2002-05-07 2002-05-07 Utilisation de novirhabdovirus modifies pour l'obtention de vaccins
PCT/FR2003/001413 WO2003097090A1 (fr) 2002-05-07 2003-05-07 Utilisation de novirhabdovirus modifies pour l'obtention de vaccins.

Publications (2)

Publication Number Publication Date
NO20044901L true NO20044901L (no) 2005-01-17
NO328272B1 NO328272B1 (no) 2010-01-18

Family

ID=29286344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044901A NO328272B1 (no) 2002-05-07 2004-11-10 Modifisert, rekombinant novirhabdovirus, komplementaere DNA-molekyler av genomet av nevnte novirhabdovirus, rekombinant vektor omfattende nevnte DNA-molekyl, vaksine omfattende nevnte novirhabdovirus, DNA-molekyl eller vektor for a oppna et medisinsk produkt.

Country Status (7)

Country Link
US (1) US20060063250A1 (no)
EP (2) EP2292262A3 (no)
AU (1) AU2003260540A1 (no)
CA (1) CA2483712A1 (no)
FR (1) FR2839453B1 (no)
NO (1) NO328272B1 (no)
WO (1) WO2003097090A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339131C (zh) * 2002-09-17 2007-09-26 诺瓦提斯公司 用于免疫刺激的ihnv g蛋白
US7501128B2 (en) 2002-09-17 2009-03-10 Novartis Animal Health Us, Inc. IHNV G protein for immune stimulation
DK179025B1 (da) 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
CA2796178C (en) 2010-04-21 2021-02-16 Pharmaq As Nucleic acid sequences of fish cardiomyopathy syndrome virus and the use thereof
FR2996856B1 (fr) 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CN112098658B (zh) * 2020-09-16 2024-04-05 中国海洋大学 一种牙鲆弹状病毒病感染态与免疫态的快速诊断试纸
CN113144185A (zh) * 2021-04-12 2021-07-23 中国水产科学研究院黑龙江水产研究所 一种传染性造血器官坏死病疫苗及其病毒在胖头鱥上皮细胞上扩增的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492841B1 (fr) * 1980-10-23 1983-07-22 Agronomique Inst Nat Rech Virus mutant de septicemie hemorragique virale, vaccin contenant ce mutant et procede pour sa preparation
ES2210273T5 (es) 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. Virus con arn de cadena negativa no segmentado recombinante infeccioso.

Also Published As

Publication number Publication date
NO328272B1 (no) 2010-01-18
AU2003260540A1 (en) 2003-12-02
EP1501543A1 (fr) 2005-02-02
FR2839453B1 (fr) 2007-05-11
US20060063250A1 (en) 2006-03-23
WO2003097090A1 (fr) 2003-11-27
EP2292262A2 (fr) 2011-03-09
CA2483712A1 (fr) 2003-11-27
EP2292262A3 (fr) 2011-11-09
FR2839453A1 (fr) 2003-11-14

Similar Documents

Publication Publication Date Title
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1124931T1 (el) Αντιμετωπιση της φαινυλκετονουριας με bh4
ATE543873T1 (de) Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase
ATE429225T1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase- enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
EA200702374A1 (ru) Анти-il-6 антитела, композиции, способы их получения и применения
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
MY140539A (en) 1-amino 1h-imidazoquinolines
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
BR0313492A (pt) Formulação de anticorpos humanos para tratar distúrbios associados ao tnf-alfa
CY1112590T1 (el) 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
EP1503795A4 (en) USE OF STRESS PROTEINS TO IMPROVE THE EFFICIENCY OF THERAPEUTIC ANTIBODIES
ATE512668T1 (de) Allogenes tumortherapeutikum
NO20044901L (no) Anvendelse av modifiserte novirhabdoviruser i vaksiner
ATE516366T1 (de) Regulierte aptamer-therapeutika
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
ATE492631T1 (de) Verwendung von mutationen zur verbesserung von aspergillus-phytasen
ATE275143T1 (de) Verbindungen
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
DE60325494D1 (de) Sirna-gesteuerte genexpressionsunterdrückung in transgenetischen tieren
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
ATE362535T1 (de) Mutiertes cyclin g1 protein

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees